Plasticity of the nigropallidal pathway in Parkinson's disease

Annals of Neurology

Volumn 53, Issue 2, 2003, Pages 206-213

  Whone, Alan L ^a   Moore, Robert Y ^b   Piccini, Paola P ^a   Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPA; DOPAMINE; FLUORINE 18;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GLOBUS PALLIDUS; HUMAN; MOTOR CORTEX; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NERVE PROJECTION; NIGROPALLIDAL PATHWAY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS VENTRAL NUCLEUS;

ADULT; AGED; BRAIN MAPPING; GLOBUS PALLIDUS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEURAL PATHWAYS; NEURONAL PLASTICITY; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0037307956     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10427     Document Type: Article

References (29)

1. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nat New Biol 1973;245: 150-151.
2. Zigmond MJ, Abercrombie ED, Berger TW, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
3. Bezard E, Gross CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 1998;55:93-116.
4. Hornykiewicz O. Compensatory biochemical changes at the striatal dopamine synapse in Parkinson's disease. In: Norabayashi N, Nagatsu N, Yanagisawa Y, Mizuno Y, eds. Advances in neurology. New York: Raven Press, 1993:275-281.
5. Hoogendijk WJG, Feenstra MG, Botterblom MH, et al. Increased activity of surviving locus coeruleus neurons in Alzheimer's disease. Ann Neurol 1999;45:82-91.
6. Morrish PK, Rakshi JS, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period in Parkinson's disease. J Neurol Neurosurg Psychiat 1998;64: 314-319.
7. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996;119:2097-2103.
8. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
9. 18F]dopa PET study. Brain 1999;122:1637-1650.
10. Spinks TJ, Jones T, Bloomfield PM, et al. Physical characteristics of the ECAT EXACT 3D positron tomograph. Phys Med Biol 2000;45:2601-2618.
11. Patlak CS, Blasberg RG. Graphical evaluation of blood to brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
12. Sawle GV, Colebatch JG, Shah A, Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28:799-804.
13. Snow BJ Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34: 324-330.
14. Pare BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
15. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
16. Lindvall O, Bjorklund A. Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway. Brain Res 1979;172:169-173.
17. Parent A, Lavoie B, Smith Y, et al. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Adv Neurol 1990;53: 111-116.
18. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 2000; 23(suppl):S28-S33.
19. Parent A, Smith Y. Differential dopaminergic innervation the two pallidal segments in the squirrel monkey (Saimiri sciureus). Brain Res 1987;426:397-400.
20. Parent A, Martine C. Extrastriatal dopamine and Parkinson's disease. Adv Neurol 2001;86:45-54.
21. Parent A, Sato F, Wu Y, et al. Organization of the basal ganglia: the importance of axonal collaterization. Trends Neurosci 2000;10(suppl):S20-S27.
22. Gauthier J, Parent M, Levesque M, Parent A. The axonal arborization of single nigrostriatal axons in rats. Brain Res 1999; 834:228-232.
23. Jellinger KA. Postmortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm 1999;56(suppl):1-29.
24. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122: 1437-1448.
25. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
26. Parent A, Hazrati L. Anatomical aspects of information processing in primate basal ganglia. Trends Neurosci 1993;16: 111-116.
27. Obeso JA, Rodiguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(suppl):S8-S19.
28. Hauber W, Lutz S. Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat. Behav Brain Res 1999;106:143-150.
29. Galvan A, Floran B, Erlij D, Aceves J. Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat. J Neural Transm 2001;108:153-166.